Children's Hospital of Michigan is revolutionizing beta thalassemia treatment with the groundbreaking gene therapy Zynteglo. This innovative approach involves adding a gene to the patient's bone marrow stem cells, eliminating the need for lifelong interventions and mitigating side effects. Eligible patients can now undergo potentially curative treatment at the hospital, known for its expertise in stem cell transplantation and gene therapy. This milestone reflects the hospital's commitment to exceptional care and fulfills the vision of its founder, Dr. Thomas Benton Cooley. Zynteglo offers hope and relief, particularly for patients of Mediterranean, South Asian, and Middle Eastern descent disproportionately affected by this genetic condition.
Click here to learn more about this life-altering treatment.
Click the button below to see an alphabetical listing of our faculty, where you can learn more about each physician's specialty, education, publications, and more.
UP is committed to advancing child health through research, scholarship and advocacy under the Central Michigan University College of Medicine/University Pediatrics Clinical Research Institute (CRI). CRI is the nexus for clinical and preclinical research at the Children’s Hospital of Michigan.
Click the button below to learn more about CRI, and view the CMU Discipline of Pediatrics annual progress report for information on our faculty's latest grants, publications, awards, and more.